<DOC>
	<DOCNO>NCT01772927</DOCNO>
	<brief_summary>Numeta G13 % triple chamber bag include amino acid plus electrolyte , glucose lipid , dedicate parenteral nutrition preterm newborn infant oral/enteral nutrition possible , insufficient contra indicate . The product register 18 country Europe via decentralized procedure end 15th December 2010 . The present study want evaluate use Numeta 13 % standard medical prescription NICU university Liege . It prospective , monocentric , non-interventional , non comparative , open-labeled data collection record keep , nutritional intake bag , additional intake well blood urine biochemical marker currently evaluate NICU . The data collect VLBWI &lt; 1500 g receive Numeta G13 % day birth ( day 1 ) parenteral nutrition ( PN ) decrease 20 % target intake 2 day row quality control new solution clinical practice . Indication PN daily prescription follow protocol use NICU behalf investigator</brief_summary>
	<brief_title>Clinical Tolerance Numeta 13 %</brief_title>
	<detailed_description>Background information The multichamber bag parenteral solution specially design preterm infant develop provide adequate appropriate mixture macronutrients ( amino acid , carbohydrate , lipid ) micronutrient ( electrolyte , vitamin , trace-elements ) either peripheral central vein range recent nutritional recommendation ELBW , VLBW LBW infant require total partial parenteral nutrition ( Tsang &amp; al 2005 , Espghan-ESPEN Commentary 2005 ) . The multichamber bag parenteral solution preterm infant NumetaG13 % evaluate phase III study entitle : `` Safety use triple chamber bag formula , administer IV 5 10 consecutive day , preterm infant require parenteral nutrition . '' EudraCT Number : 2007-001378-97 ; PPM Number : 36830247 It prospective , multicentre , non-comparative phase III study limit 5 10 day parenteral nutrition . Preterm infant include without restriction postnatal age accord need inform parental consent , 30 % patient include first 3 day life . Weight gain nutritional intake multichamber bag parenteral solution , additional parenteral oral supply collect daily study . Biochemical parameter record study limit BUN , glycemia , triglyceridemia , natremia , kaliemia , calcemia , phosphatemia plasma bicarbonate concentration collect inclusion , 5 &amp; 10 day parenteral nutrition . Performance safety assess collection vital sign adverse event whereas , information handle administration Ped3CB evaluate use visual scale parameter . Results study summarized manuscript recently publish JPGN 2012 refer . J. Rigo , ML . Marlowe , D. Bonnot , Th . Senterre , A. Lapillonne , E. Kermorvant-Duchemin , JM . Hascoet , R. Desandes , G. Malfilatre , P. Pladys , A. Beuchee , Virginie Colomb . Benefits New Pediatric Triple-Chamber Bag Parenteral Nutrition Preterm Infants . JPGN2012 ; 54 : 210-217 Numeta 13 % register 18 country Europe via decentralized procedure end 15th December 2010 . In NICU University Liege , decide use Numeta 13 % standard parenteral solution preterm infant first day life therefore perform quality control evaluation balance parenteral solution first day life preterm infant birth weight &lt; 1500 g. collect nutritional intake bag , additional intake well blood urine biochemical marker currently evaluate NICU . In context , recently report use ready use binary parenteral solution compound pharmacy hospital possible provide nutritional intake range recommendation ( Tsang 2005 , ESPGHAN-ESPEN 2005 ) , abolish cumulative nutritional deficit frequently observe preterm infant limit postnatal growth restriction preterm infant birth weight &lt; 1250 g. ( Senterre Th Rigo J JPGN 2011 , Acta Paediatrica 2012 ) . In study , suggest use birth RTU parenteral solution contain electrolyte , mineral high protein ( AA ) : energy ratio improve clinical tolerance reduces metabolic disturbance first week life group preterm infant ( Senterre Th Rigo J Manuscript preparation ) Objective study The aim present study provide information medical staff medical community adequacy use flexibility Numeta 13 % . provide recommend nutritional intake evaluate daily biochemical tolerance , safety issue administer first day life significant population low birth weight infant ( VLBWI ) . The secondary objective compare clinical tolerance biochemical laboratory data obtain Numeta 13 % recently publish similar population use compounded solution prepare hospital pharmacy . Study Design The study carry prospective , monocentric , open label phase IV study therapeutic use.The hospital pharmacist dispense clinical department Paediatric 3CB patient use . The recruitment perform base consecutive admission rate . Nevertheless , recruitment balance accord birth weight ( &lt; 1000 g , 1000- &lt; 1250 g &gt; 1250 g ) ensure patient distribution range ELBW VLBW infant . In patient fulfil inclusion criterion , intravenous nutrition administer use Numeta 13 % end parenteral support need . Prescription Numeta 13 % follow guideline parenteral nutrition define NICU University Liege Belgium . Activation non-activation lipid bag discretion neonatologist charge preterm infant . Nutritional intake ( parenteral oral ) , body weight , biochemical laboratory data , insulin need , clinical data additional treatment record every day , last infusion day . Prescription blood urinary biochemical survey perform neonatologist charge preterm infant record . When several data identical parameter request day , maximal minimal data record mean value calculate . Safety evaluation conduct birth include daily monitor biochemical laboratory data ( plasma ionogram , mineral , pH , glucose , BUN triglycerides ) accord biological prescription well daily collection supplementation need , vital sign adverse event . Treatment Parenteral support : Numeta 13 % administration adapt body weight , postÂ¬natal age , oral/enteral tolerance intake , accord current nutritional guideline ( ESPEN-ESPGHAN 2005 , Tsang 2005 ) . The protocol use NICU University Liege use gather table I II accord activation lipid bag Numeta 13 % administered daily mainly central venous catheter . When peripheral supplemental parenteral nutrition indicate , dilution Numeta 13 % solution perform order limit osmolality perfusion value &lt; 900 mosm/L .</detailed_description>
	<mesh_term>Failure Thrive</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>All preterm infant &lt; 1500 g require parenteral nutrition first day , include study base consecutive admission rate . However , In order representative ELBW VLBW population NICU , inclusion limit first 15 VLBW infant category , ( &lt; 1000 g , 1000 &lt; 1250 g 1250 &lt; 1500 g ) . An additional recruitment 5 infant category group necessary obtain least 10 infant receive significant parenteral nutritional supply final analysis . preterm infant die first day life &lt; 7 day , preterm infant receive early oral nutrition intake &gt; 50 % nutritional requirement 5 7 day life , preterm infant contraindication conventional Parenteral Nutrition ( inborn error metabolism , severe multiorgan failure ) exclude per protocol analysis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Days</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>parenteral nutrition</keyword>
	<keyword>Very low birth weight infant</keyword>
	<keyword>preterm infant</keyword>
	<keyword>biochemical tolerance</keyword>
	<keyword>nutritional intake</keyword>
</DOC>